Agile Therapeutics, Inc.
AGRX · NASDAQ
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | -0.00 | 0.03 |
| FCF Yield | 2.40% | -197.98% | 2.98% | 5.16% |
| EV / EBITDA | -2.60 | 0.37 | -1.37 | -18.68 |
| Quality | ||||
| ROIC | 25.02% | 32.62% | 47.95% | 100.63% |
| Gross Margin | 73.17% | 70.61% | 39.37% | 62.82% |
| Cash Conversion Ratio | -0.02 | -1.93 | -0.04 | -0.46 |
| Growth | ||||
| Revenue 3-Year CAGR | 47.74% | 55.23% | 68.41% | 81.57% |
| Free Cash Flow Growth | 109.41% | -1,539.53% | -52.88% | 104.28% |
| Safety | ||||
| Net Debt / EBITDA | 0.93 | 0.85 | 0.10 | 0.99 |
| Interest Coverage | 0.00 | -14.90 | -13.29 | -11.73 |
| Efficiency | ||||
| Inventory Turnover | 0.26 | 0.45 | 0.80 | 1.03 |
| Cash Conversion Cycle | -573.28 | -399.50 | -196.33 | -114.77 |